Recently, the first oral GLP-1 agonist called Rybelsus (semaglutide) was approved by the FDA
Regarding safety profile, in phase 2 trials for obesity and diabetes, mazdutide was discontinued due to AE by 02% of participants and SAE experienced by up to 7% of participants with mazdutide 6 mg (Tables 2 and 3)
Bariatric surgery is more cost-effective than GLP-1 drugs April 29, 2024 Source: Haseeb, et al JAMA Network Open April 12, 2024 LINK GLP-1 drugs are highly effective, and on average people are able to lose about 15% of their body weight with weekly self-injections
Current reviews in musculoskeletal medicine, 18(10), 469480
Sometimes, if something seems too good to be true, it may be too good to be true
Oral semaglutide contains an absorption enhancer called salcaprozate sodium, which helps the peptide survive the digestive tract and reach the bloodstream